Price$232.15-1.39 (-0.60%)
01:30 PM07:45 PM
News · 26 weeks127-71%
2025-12-142026-06-07
Mix5790d
- Other32(56%)
- Insider15(26%)
- SEC Filings5(9%)
- Analyst2(4%)
- Earnings2(4%)
- Dividends1(2%)
Latest news
25 items- PRJohnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate PlatformExpands the Company's expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform for KRAS-driven tumors bolsters Johnson & Johnson's oncology pipeline and ambition
- PRJohnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseaseNipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren's disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and painNipocalimab is the only FcRn blocker
- PRJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigmPatients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of MedicineCHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized
- PRRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerMedian overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomesASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutationsCHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypica
- PRNew TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myelomaBuilding on the recent approval of Johnson & Johnson's TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second line TECVAYLI® delivered deep and durable responses with nearly two-thirds of patients achieving a complete response or betterCHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with TECVAYLI® (teclistamab-cqyv) versus standard of care regim
- PRFDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damageTREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritisHORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). The inclusion of this key outcome reflects that TREMFYA is the only IL-23 inhibitor proven to help stop further structural damage, offering patients with active PsA a first-line treatment option that provides effective symptom
- PRJohnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsJohnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the w
- SECSEC Form SD filed by Johnson & JohnsonSD - JOHNSON & JOHNSON (0000200406) (Filer)
- SECSEC Form 13F-HR filed by Johnson & Johnson13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
- PRCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) are responding to this challenge with next-generation delivery pla
- ANALYSTJohnson & Johnson upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00
- PRJohnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9th, 2026. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511295368/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com
- PRJohnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCPOral presentations feature CAPLYTA® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms18 abstracts highlight J&J's leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual MeetingsTITUSVILLE, N.J., May 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) Annual Meeti
- PRJohnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for RemissionGeneration Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remissionCampaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player NEW BRUNSWICK, N.J., May 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel "fine" in depression care and empower patients to take the first step in moving beyond "good enough" by talking with their healthcare
- PRJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel diseaseJNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to two or more systemic therapy classesJNJ-4804 is the first and only fixed dose co-antibody designed to deliver molecular synergy in IBD by blocking the complementary IL-23 and TNF pathwaysData from Phase 2b DUET studies show potential to address a critical unmet need and support advancement to Phase 3 trialsCHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both inte
- PRJohnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic SystemStudy results represent a critical milestone for the investigational OTTAVA™ Robotic Surgical System Data demonstrates feasibility of novel system architecture with table‑integrated robotic arms in space‑constrained ORs Abstract presented at the 2026 American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting Presidential Grand Round Sessions in San Antonio, Texas Today, Johnson & Johnson announced results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System – a prospective, multicenter clinical study evaluating the safety and performance of the system in Roux-en-Y gastric bypass procedures. The results were presented at the 2026 America
- INSIDEREVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 134% to 24,911 units (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- PRJohnson & Johnson Appoints Ryan Koors as Vice President, Investor RelationsJohnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430443361/en/Ryan Koors, Vice President, Investor Relations, Johnson & Johnson, effective May 7, 2026. "Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitm
- SECJohnson & Johnson filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- INSIDERSEC Form 4 filed by Director Woods Eugene A.4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director West Nadja4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Weinberger Mark A4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Pinto Daniel E4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Morikis John G4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcclellan Mark B.4 - JOHNSON & JOHNSON (0000200406) (Issuer)
JNJ FAQ
7 questionsWhat does Johnson & Johnson do?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL...Where does JNJ stock trade?
Johnson & Johnson (JNJ) is listed on NYSE.What sector and industry is JNJ in?
Johnson & Johnson operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does JNJ pay a dividend?
JNJ's most recent ex-dividend date was 2026-05-26 with a cash dividend of $1.34 per share. No future ex-date is on file yet.What are analysts saying about JNJ?
Johnson & Johnson has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform on 2026-05-13.What companies are similar to JNJ?
Notable peers in the same industry include AZN (AstraZeneca PLC), MRK (Merck & Company Inc.), NVS (Novartis AG), PFE (Pfizer Inc.), UL (Unilever PLC). Compare JNJ side-by-side with any of them on Quantisnow.How can I track JNJ on Quantisnow?
Quantisnow aggregates Johnson & Johnson's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JNJ to receive live email and push alerts on every new disclosure.